LY-310762

LY-310762 is a drug that was developed for the treatment of migraines. It acts as a 5-HT1D receptor antagonist, and has a novel mechanism of action. Despite showing promise in animal models, it was not effective in reducing migraine symptoms in a clinical trial.

History

LY-310762 was developed by Eli Lilly and Company, a pharmaceutical company based in the United States. The drug was designed to target the 5-HT1D receptor, a subtype of the 5-HT receptor that is thought to be involved in the pathophysiology of migraines.

Mechanism of action

LY-310762 is a 5-HT1D receptor antagonist. The 5-HT1D receptor is a G protein-coupled receptor that is activated by the neurotransmitter serotonin. By blocking this receptor, LY-310762 is thought to inhibit the release of calcitonin gene-related peptide, a molecule that is involved in the transmission of pain signals in the brain.

Clinical trials

Despite showing promise in animal models, LY-310762 was not effective in reducing migraine symptoms in a clinical trial. The reasons for this lack of efficacy are not fully understood, but it is thought that the drug may not have been able to reach the necessary concentrations in the brain due to poor bioavailability.

See also

• 5-HT1D receptor
• Migraine
• Eli Lilly and Company

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia